Sabicard 49 mg+51 mg (Tablet)
Unit Price: ৳ 85.00 (1 x 10: ৳ 850.00)
Strip Price: ৳ 850.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Aristopharma ltd |
| Also available as |
Indications
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- Administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.
Pharmacology
- Contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan.
- Inhibits neprilysin (NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1) receptor via valsartan.
- Cardiovascular and renal effects attributed to increased levels of peptides degraded by neprilysin, such as natriuretic peptides, and simultaneous inhibition of the effects of angiotensin II by valsartan.
Dosage & Administration
- Recommended starting dose for adult heart failure: 49/51 mg orally twice daily.
- Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
- Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.
- Recommended starting dose for pediatric patients less than 40 kg: 1.6 mg/kg.
Interaction
- Dual Blockade of the Renin-Angiotensin-Aldosterone System should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
- Potassium-sparing Diuretics may increase serum potassium level.
- NSAIDs may increase the risk of renal impairment.
- Lithium may increase the risk of lithium toxicity.
Contraindications
- Contraindicated in patients with hypersensitivity to any component.
- Contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy.
- Do not administer within 36 hours of switching from or to an ACE inhibitor.
- Contraindicated with concomitant use of aliskiren in patients with diabetes.
Side Effects
- Common side effects include Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age.
- No relevant pharmacokinetic differences observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
Precautions & Warnings
- May cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.
- Lowers blood pressure and may cause symptomatic hypotension.
- Monitor serum potassium periodically and treat appropriately.
Use in Special Populations
- Safety and effectiveness in pediatric patients have not been established.
- No starting dose adjustment is needed for mild or moderate renal impairment.
Overdose Effects
- Hypotension is the most likely result of overdosage.
- Symptomatic treatment should be provided.
- Unlikely to be removed by hemodialysis because of high protein binding.
Storage Conditions
- Keep in a dry place and store below 30°C.
- Protect from moisture and keep out of the reach of children.